Zinzino Preliminary Sales Report, April 2025

Zinzino group revenue increased with a total of 54 %, compared with the previous year.

The revenue in April for Zinzino’s sales markets increased by 58 % and amounted to SEK 249.5 (158.0) million. Faun Pharma’s external sales decreased and amounted to SEK 6.2 (8.2) million.

Overall, the Group increased revenues by 54 % to SEK 255.7 (166.2) million compared with the previous year.

Accumulated revenue for January–April 2025 increased by 58 % to SEK 979.4 (620.7) million.

Revenues were distributed as follows:

Countries in regions:

• The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden

• Central Europe: Austria, Germany, Switzerland

• East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania

• South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands

• The Baltics: Estonia, Latvia, Lithuania

• North America: Canada, USA, Mexico

• Asia-Pacific: Australia, New Zealand, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand

• Africa: South Africa

To view the full press release, please visit zinzino.com

About Zinzino

Zinzino is a global direct sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their scientifically proven nutritional supplements are available in more than 100 markets across the world.

Zinzino has acquired all assets in the health and wellness companies Zurvita and Xelliss. The company co-owns the Cypriot olive oil producer Cleanthi Alpha-Olenic LTD, and owns the Swiss biotech skincare brand HANZZ+HEIDII, as well as the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden, with additional offices in Europe, Asia, and Australia.